Letter: Demarcation Line of Tissue Compaction in Traumatic Brain Herniation: A Conceptual and Clinical Model

To the Editor We read with interest the recent article by Mustafayev et al, “Demarcation Line of Tissue Compaction in Traumatic Brain Herniation: A Conceptual and Clinical Model,”1 which proposes that supratentorial herniation be conceptualized as a vertically propagating “compaction front” and introduces a putative physiobiological boundary, the “demarcation line of tissue compaction”, that separates potentially salvageable tissue from irreversible failure. The authors further suggest a prodromal “Hyper-H triad” (hyperthermia, hypertonia, hormonal dysregulation) that precedes later brainstem failure. The effort to unify bedside signs, autonomic markers (Kerdo vegetative index), and postmortem morphology into a clinically usable staging framework is valuable and aligns with a long-standing need in neurocritical care: to translate evolving physiology into actionable, time-sensitive decisions. However, several methodological and interpretive issues limit the article’s current translational impact: First, the model risks relabeling established physiology rather than demonstrating a new mechanism. The authors define traumatic brain herniation as a staged rostrocaudal syndrome and then use the same clinical variables (pupils, oculocephalic reflexes, motor patterns, respiration, and Kerdo index) to infer the presence and location of a compaction boundary. This is close to circular validation: the staging is built from neurological signs, and the proposed “front” is then “confirmed” by those same signs. In its present form, the article convincingly documents a reproducible sequence of neurological deterioration, but it does not yet establish that a discrete, measurable “demarcation line” exists in vivo or that it can be operationalized for monitoring or decision-making. A practical path forward would be to anchor “compaction” in independent, quantifiable correlates—eg, diffusion restriction patterns, perfusion gradients, computed tomography or MRI tissue-density imaging correlates, elastance/compliance physiological indices, or multimodal monitoring [intracranial pressure (ICP)/cerebral perfusion pressure (CPP), oxygenation, and autoregulatory indices]. Importantly, the Brain Trauma Foundation's severe traumatic brain injury guidelines explicitly emphasize that monitoring improves outcomes only when data guide treatment, and they continue to support ICP- and CPP-informed management as outcome-relevant monitoring strategies.2 Any proposed frontier between salvageable and nonsalvageable tissue should be tied to monitored variables that can inform real-time management. Second, internal inconsistencies in stage counts undermine stage-linked inference. In the results narrative, the distribution across stages is reported as stage I 118 (41.1%), II 74 (25.8%), III 61 (21.3%), IV 23 (8.0%), and V 11 (3.8%). Yet, Table 2 reports different n and percentages (I 110, II 83, III 63, IV 19, V 12). This discrepancy is not without significance value: it affects denominators, stage prevalence, and any statistical associations among stage, the Kerdo index, and outcome. If the model's clinical utility depends on stage assignment, the underlying counts must be reconciled transparently (including how missing data, transfers, early deaths, and postmortem subset selection were handled). Third, the Hyper-H triad requires clearer phenotyping and stronger separation from confounders. The illustration description presents Hyper-H as preceding the Cushing triad and implies a transition from hypothalamic dysregulation to structural brainstem failure. Yet, “hormonal dysregulation” is acknowledged as rarely measured in the staging table (and seems to be absent later), raising uncertainty about ascertainment, thresholds, and timing. In severe traumatic brain injury, hyperthermia and tone abnormalities are heavily confounded by sedation, neuromuscular blockade, seizures, infection, transfusion, and systemic shock; endocrine abnormalities (eg, syndrome of inappropriate antidiuretic hormone/cerebral salt wasting) may reflect critical illness physiology rather than a specific herniation prodrome. Without explicit measurement protocols (which hormones, at what intervals, with what cutoffs, and how treatment alters expression), Hyper-H risks being an attractive narrative construct that may not be reproducible across centers. Fourth, “compaction” should be interpreted within cerebrovascular physiology, not as a replacement for it. Classic work on intracranial dynamics emphasizes that deterioration can follow nonlinear shifts in ICP–cerebral blood flow coupling and perfusion gradients.3 In their continuous ventricular pressure recordings, Lundberg and colleagues demonstrated marked spontaneous ICP variability (“plateau waves”) and, critically, that brainstem dysfunction may arise from either direct brainstem injury with normal ICP or from herniation-related compression, an empiric distinction with clear management implications. Lundberg further described the terminal “vicious circle” in which hypotension plus elevated ICP collapses effective cerebral perfusion, accelerating edema and irreversible injury. These observations suggest that a “front” (if it exists) may be less a purely mechanical compaction phenomenon and more an evolving perfusion–autoregulation failure that should be mapped against contemporaneous ICP, arterial pressure, and CPP trends—precisely the variables emphasized by modern guideline-based care. In summary, Mustafayev et al present a compelling descriptive staging of rostrocaudal decline, supported by postmortem anatomic correlations, and their clinical framework may help standardize bedside communication. To elevate the proposal from a conceptual hypothesis to a clinically testable model, the authors should (1) resolve Data set inconsistencies, (2) predefine objective criteria for Hyper-H, report measurement frequency and confounder control, and (3) validate “compaction” against independent in vivo physiological and imaging markers integrated with ICP/CPP-directed care. Such steps would clarify whether the “demarcation line” is a measurable therapeutic threshold—or a reframing of already recognized neurophysiological collapse. The clinically meaningful transition may not conform to a sagittal vertex-to-bulbar axis, but instead may reside within the axial plane at the mesencephalic-posterior communicating artery level, a region that plausibly demarcates the boundary between salvageable supratentorial dysfunction and irreversible brainstem failure.